title: Accelerated Restoration of Ocular Surface Health in Dry Eye Disease by Self-Retained Cryopreserved Amniotic Membrane.
abstract: OBJECTIVE
  To evaluate the clinical efficacy of self-retained cryopreserved amniotic membrane in treating dry eye disease.
  
  
  METHODS
  Retrospective review of 10 patients treated with self-retained cryopreserved amniotic membrane (PROKERA® Slim [PKS], Bio-Tissue, Miami, FL) for moderate-to-severe dry eye refractory to conventional maximal medical treatments. Patients' symptoms, use of medications, conjunctival inflammation, corneal staining, and visual acuity were compared before and after treatment.
  
  
  RESULTS
  PKS was placed in 15 eyes of the 10 patients for 4.9 ± 1.5 days. All patients experienced symptomatic relief for a period of 4.2 ± 4.7 months (P<.001). Such improvement was accompanied by reduction of OSDI scores (P<.001), use of topical medications (P<.001), conjunctival hyperemia (P<.001), corneal staining (P<.001), and improvement of the visual acuity (P=.06). Linear regression analysis estimated that the optimal duration of PKS placement was 5 days to achieve an average symptom-free duration of 4 months in patients with dry eye. Surprisingly, PKS placement also generated improvement in the contralateral eyes.
  
  
  CONCLUSIONS
  This pilot study suggests that self-retained cryopreserved amniotic membrane via PKS can be used to treat moderate dry eye diseases and warrants further prospective controlled studies.
authors.affiliation: Ocular Surface Center and Tissuetech Inc., Miami FL, USA.
authors.forename: Anny M S
authors.initials: AM
authors.lastname: Cheng
authors.affiliation: Department of Ophthalmology, Yan'An Hospital of Kunming City, Kunming, Yunnan, China.
authors.forename: Dandan
authors.initials: D
authors.lastname: Zhao
authors.affiliation: Department of Ophthalmology, Shenzhen Children's Hospital, Shenzhen, Guangzhou, China.
authors.forename: Rendian
authors.initials: R
authors.lastname: Chen
authors.affiliation: Florida International University Herbert Wertheim College of Medicine, Miami, FL, USA.
authors.forename: Han Y
authors.initials: HY
authors.lastname: Yin
authors.affiliation: Ocular Surface Center and Tissuetech Inc., Miami FL, USA.
authors.forename: Sean
authors.initials: S
authors.lastname: Tighe
authors.affiliation: Ocular Surface Center and Tissuetech Inc., Miami FL, USA.
authors.forename: Hosam
authors.initials: H
authors.lastname: Sheha
authors.affiliation: Ocular Surface Center and Tissuetech Inc., Miami FL, USA.
authors.forename: Victoria
authors.initials: V
authors.lastname: Casas
authors.affiliation: Ocular Surface Center and Tissuetech Inc., Miami FL, USA. Electronic address: stseng@ocularsurface.com.
authors.forename: Scheffer C G
authors.initials: SC
authors.lastname: Tseng
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000650:Amnion / Q000637:transplantation*; D015925:Cryopreservation / Q000379:methods*; D015352:Dry Eye Syndromes / Q000503:physiopathology / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D020127:Recovery of Function; D012189:Retrospective Studies; D014792:Visual Acuity / Q000502:physiology*
keywords: PROKERA®; amniotic membrane; dry eye; keratitis; ocular surface